<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03302910</url>
  </required_header>
  <id_info>
    <org_study_id>R01HS025411</org_study_id>
    <nct_id>NCT03302910</nct_id>
  </id_info>
  <brief_title>Short Stay Unit vs Hospitalization in Acute Heart Failure</brief_title>
  <acronym>SSU-AHF</acronym>
  <official_title>Using Short Stay Units Instead of Routine Admission to Improve Patient Centered Health Outcomes for AHF Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indiana University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Agency for Healthcare Research and Quality (AHRQ)</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Indiana University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The majority of the over one million annual AHF hospitalizations originate from the emergency
      department. Admitting and re-admitting lower risk AHF patients who don't need prolonged
      hospitalization may increase their risk for poor outcomes and decrease their quality of life:
      Safe alternatives to hospitalization from the ED are needed. We propose a strategy-of-care,
      short stay unit management of AHF (i.e. less than 24 hours), will lead to improved outcomes
      for lower risk AHF patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Nearly 85% of acute heart failure (AHF) patients who present to the emergency department (ED)
      with acute heart failure (AHF) are hospitalized. Once hospitalized, within 30 days
      post-discharge, 27% of patients are re-hospitalized or die. Attempts to improve outcomes with
      novel therapies have all failed. The evidence for existing AHF therapies are poor: No
      currently used AHF treatment is known to improve outcomes. ED treatment is largely the same
      today as 40 years ago. Hospitalizing patients who don't need it may contribute to adverse
      outcomes. Hospitalization is not benign; patients enter a vulnerable phase post-discharge, at
      increased risk for morbidity and mortality. Patients would prefer to be home, not
      hospitalized. Furthermore, hospitalization and re-hospitalization for AHF predominantly
      affects patients of lower socioeconomic status (SES). Avoiding hospitalization in patients
      who don't need it may improve outcomes and quality of life, while reducing costs.

      Short stay unit (SSU: less than 24 hours) management of AHF is effective for lower risk
      patients. However, it's only been studied in small studies or retrospective analyses. In
      addition, some have considered the SSU 'cheating' for hospitals trying to avoid 30 day
      readmission penalties, since SSU or observation didn't count as an admission. However, this
      quality measure is now changing. A robust clinical effectiveness trial would demonstrate the
      effectiveness of this patient-centered strategy.

      Using a multi-center, randomized controlled design, this clinical effectiveness trial will
      test whether Short Stay Unit AHF management for &lt; 24 hours increases
      days-alive-and-out-of-hospital, Quality of Life assessment (QoL), caregiver burden, and costs
      compared to inpatient management.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 6, 2017</start_date>
  <completion_date type="Anticipated">June 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Days alive and out of hospital</measure>
    <time_frame>30 day outcome</time_frame>
    <description>To demonstrate the effectiveness of a SSU AHF management strategy vs standard of care</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life as measured by Kansas City Cardiomyopathy Questionnaire</measure>
    <time_frame>30 day outcome</time_frame>
    <description>To determine quality of life using a heart failure questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost Effectiveness Analysis</measure>
    <time_frame>30 day outcome</time_frame>
    <description>Determine differences in costs between the two strategy of care arms</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Caregiver Burden</measure>
    <time_frame>30 and 90 days</time_frame>
    <description>Measure caregiver burden</description>
  </other_outcome>
  <other_outcome>
    <measure>Cost Effectiveness Analysis</measure>
    <time_frame>90 days</time_frame>
    <description>Determine differences in costs between the two strategy of care arms</description>
  </other_outcome>
  <other_outcome>
    <measure>Modified Resource Utilization Questionnaire for Heart Failure</measure>
    <time_frame>30 days</time_frame>
    <description>Measures resource utilization</description>
  </other_outcome>
  <other_outcome>
    <measure>All cause mortality and re-hospitalization</measure>
    <time_frame>30 and 90 days from randomization</time_frame>
    <description>Assessment of time to event for this composite outcome</description>
  </other_outcome>
  <other_outcome>
    <measure>Days alive and out of hospital</measure>
    <time_frame>90 days</time_frame>
    <description>To demonstrate the effectiveness of a SSU AHF management strategy vs standard of care</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">534</enrollment>
  <condition>Acute Heart Failure</condition>
  <arm_group>
    <arm_group_label>Short Stay Unit</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects are assigned to the short stay unit (SSU) for approximately 23 hours treatment and observation period. In the SSU, patients will receive usual care for AHF, which includes loop diuretics and nitroglycerin, as needed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects are assigned to inpatient hospitalization. During hospitalization, patients will receive usual care for AHF, which includes loop diuretics and nitroglycerin, as needed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Short Stay Unit</intervention_name>
    <description>Subjects will be treated for acute heart failure in the SSU and observed for improvement then, if appropriate, discharged. If not appropriate for discharge they will be admitted to inpatient.</description>
    <arm_group_label>Short Stay Unit</arm_group_label>
    <other_name>SSU</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard of Care</intervention_name>
    <description>Subjects who come to the ER with acute heart failure who are randomized to inpatient stay.</description>
    <arm_group_label>Standard of Care</arm_group_label>
    <other_name>SOC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Loop Diuretics</intervention_name>
    <description>IV loop diuretics are commonly used in AHF management</description>
    <arm_group_label>Short Stay Unit</arm_group_label>
    <arm_group_label>Standard of Care</arm_group_label>
    <other_name>furosemide, bumetanide, torsemide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nitroglycerin</intervention_name>
    <description>Nitroglycerin or nitrovasodilators are commonly used in AHF management</description>
    <arm_group_label>Short Stay Unit</arm_group_label>
    <arm_group_label>Standard of Care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion:

          1. ED physician clinical diagnosis of AHF;

          2. Planned admission for AHF

          3. Systolic blood pressure &gt; 100mmHg, heart rate &lt; 115bpm*

          4. Previous history of HF *Patients with atrial fibrillation but controlled HR are
             eligible

        For Caregiver Burden assessments. The eligibility criteria for a caregiver: 1) person
        either self-identifies, or when asked identifies themselves, as the primary caregiver for
        the patient. If there are multiple caregivers, the person who self-identifies as providing
        the most care will be asked to provide verbal informed consent.

        Exclusion:

          1. Transplanted organ of any kind or ventricular assist device patient;

          2. End stage renal disease, on dialysis, or eGFR &lt; 20 mL/min;

          3. Acute coronary syndrome (e.g. EKG changes consistent with ischemia or troponin
             elevation secondary to ACS);

          4. Other acute co-morbid conditions (e.g. sepsis, altered mental status) that are
             unlikely to be treated within a SSU stay;

          5. Patients who require ventilatory support of any kind or intravenous
             vasodilators/vasopressor/inotropic support. Patients who receive a one-time dose of an
             intravenious vasodiolator, but are no longer on this medication, are eligible.

          6. Pregnant patients or any patient who has been pregnant in the last 3 months

          7. &lt; 18 years of age

          8. Any patient who in the opinion of the clinician or investigator requires
             hospitalization or ICU level care or will require rehabilitation or skilled nursing
             after discharge from the ED or hospital

          9. Planned discharge from the emergency department

         10. Patients hospitalized within the last 30 days ONLY if the institution mandates these
             patients are observed. Otherwise these patients are eligible.

         11. De Novo (new Onset) AHF
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter S Pang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indiana University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Peter S Pang, MD</last_name>
    <phone>317-880-3900</phone>
    <email>ppang@iu.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mette Cole, MD</last_name>
    <phone>317-880-3900</phone>
    <email>metcol@iu.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Alabama - Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joel Rodgers</last_name>
      <email>jrodgers@uabmc.edu</email>
    </contact>
    <investigator>
      <last_name>Erik Hess</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Indiana University</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter S Pang, MD</last_name>
      <phone>312-515-4025</phone>
      <email>ppang@iu.edu</email>
    </contact>
    <contact_backup>
      <last_name>Mette Cole, MD</last_name>
      <phone>317-880-3900</phone>
      <email>metcole@iu.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Peter S Pang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wayne State University</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathleen Mays-Wilson</last_name>
      <email>kwilso10@hfhs.org</email>
    </contact>
    <investigator>
      <last_name>Joseph Miller</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beaumont Health System</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ryan Paternoster, CCRP</last_name>
    </contact>
    <investigator>
      <last_name>David Berger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Mississippi Medical Center</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rebekah Peacock</last_name>
      <email>rpeacock@umc.edu</email>
    </contact>
    <investigator>
      <last_name>Alan Jones</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63130</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Linlin Tian</last_name>
      <email>tianlinlin@wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Douglas Char</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wake Forest School of Medicine</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Elliott</last_name>
    </contact>
    <investigator>
      <last_name>Simon Mahler, MD, MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Hill, RN, BSN</last_name>
    </contact>
    <investigator>
      <last_name>Lauren Southerland, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Allegheny Health Network</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly Szabo, MPH, CCRC</last_name>
    </contact>
    <investigator>
      <last_name>Arvindo Venkat, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sean P Collins, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>UT Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Khushbakht Bakhshi</last_name>
      <email>khushbakht.bakhshi@utsouthwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Deborah Diercks</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 2, 2017</study_first_submitted>
  <study_first_submitted_qc>October 2, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 5, 2017</study_first_posted>
  <last_update_submitted>October 21, 2019</last_update_submitted>
  <last_update_submitted_qc>October 21, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Indiana University</investigator_affiliation>
    <investigator_full_name>PETER S PANG</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Acute Heart Failure, Chronic Heart Failure, Heart Failure, Heart conditions, nitroglycerin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Torsemide</mesh_term>
    <mesh_term>Furosemide</mesh_term>
    <mesh_term>Bumetanide</mesh_term>
    <mesh_term>Nitroglycerin</mesh_term>
    <mesh_term>Diuretics</mesh_term>
    <mesh_term>Sodium Potassium Chloride Symporter Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

